Pulse Biosciences Return on Equity (ROE) Growth & History (PLSE)
Pulse Biosciences's return on equity was −74.45% for fiscal 2025.
View full Pulse Biosciences company overviewPulse Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −74.45% | −7.14 pp |
| 2024 | 2024-12-31 | −67.31% | +133.16 pp |
| 2023 | 2023-12-31 | −200.47% | +149.42 pp |
| 2022 | 2022-12-31 | −349.89% | −132.56 pp |
| 2021 | 2021-12-31 | −217.33% | −31.43 pp |
| 2020 | 2020-12-31 | −185.90% | −89.13 pp |
| 2019 | 2019-12-31 | −96.78% | −29.93 pp |
| 2018 | 2018-12-31 | −66.85% | +4.88 pp |
| 2017 | 2017-12-31 | −71.72% | −22.87 pp |
| 2016 | 2016-12-31 | −48.86% | — |
Pulse Biosciences quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −29.74% | −12.55 pp |
| Q1 2026 | 2026-03-31 | −25.29% | −10.89 pp |
| Q4 2025 | 2025-12-31 | −20.11% | −0.13 pp |
| Q3 2025 | 2025-09-30 | −19.66% | +4.24 pp |
| Q2 2025 | 2025-06-30 | −17.20% | +18.79 pp |
| Q1 2025 | 2025-03-31 | −14.40% | +10.74 pp |
| Q4 2024 | 2024-12-31 | −19.99% | +4.75 pp |
| Q3 2024 | 2024-09-30 | −23.90% | −5.14 pp |
| Q2 2024 | 2024-06-30 | −35.99% | +3.78 pp |
| Q1 2024 | 2024-03-31 | −25.14% | — |
| Q4 2023 | 2023-12-31 | −24.73% | +442.00 pp |
| Q3 2023 | 2023-09-30 | −18.76% | +103.11 pp |
| Q2 2023 | 2023-06-30 | −39.77% | +23.54 pp |
| Q4 2022 | 2022-12-31 | −466.73% | −429.62 pp |
| Q3 2022 | 2022-09-30 | −121.87% | −95.21 pp |
| Q2 2022 | 2022-06-30 | −63.31% | −25.08 pp |
| Q1 2022 | 2022-03-31 | −61.16% | +24.95 pp |
| Q4 2021 | 2021-12-31 | −37.11% | +12.35 pp |
| Q3 2021 | 2021-09-30 | −26.66% | +7.71 pp |
| Q2 2021 | 2021-06-30 | −38.24% | −2.87 pp |
| Q1 2021 | 2021-03-31 | −86.11% | −40.89 pp |
| Q4 2020 | 2020-12-31 | −49.46% | −11.01 pp |
| Q3 2020 | 2020-09-30 | −34.37% | −8.51 pp |
| Q2 2020 | 2020-06-30 | −35.36% | −14.52 pp |
| Q1 2020 | 2020-03-31 | −45.22% | −29.16 pp |
| Q4 2019 | 2019-12-31 | −38.45% | −19.48 pp |
| Q3 2019 | 2019-09-30 | −25.86% | +8.24 pp |
| Q2 2019 | 2019-06-30 | −20.85% | +3.22 pp |
| Q1 2019 | 2019-03-31 | −16.07% | +3.84 pp |
| Q4 2018 | 2018-12-31 | −18.97% | −0.82 pp |
| Q3 2018 | 2018-09-30 | −34.10% | −13.89 pp |
| Q2 2018 | 2018-06-30 | −24.07% | −0.06 pp |
| Q1 2018 | 2018-03-31 | −19.91% | −7.75 pp |
| Q4 2017 | 2017-12-31 | −18.14% | −7.58 pp |
| Q3 2017 | 2017-09-30 | −20.21% | −10.72 pp |
| Q2 2017 | 2017-06-30 | −24.00% | −13.41 pp |
| Q1 2017 | 2017-03-31 | −12.15% | +0.88 pp |
| Q4 2016 | 2016-12-31 | −10.57% | — |
| Q3 2016 | 2016-09-30 | −9.49% | — |
| Q2 2016 | 2016-06-30 | −10.59% | — |
| Q1 2016 | 2016-03-31 | −13.03% | — |
Pulse Biosciences return on equity trends
Over the last five fiscal years, Pulse Biosciences's return on equity increased from −185.90% to −74.45%, a change of +111.45 percentage points. The latest reported quarter, Q2 2026, shows −29.74%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pulse Biosciences source filings ↗